Drug Database
NO

nonacog gamma (BAX 326 / Fixtera / BAX326)

✓ Approved

Baxter International, Inc. · F9 · 重组蛋白

什么是 nonacog gamma?

nonacog gamma 是一种重组蛋白,由Baxter International, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名BAX 326, Fixtera, BAX326
公司Baxter International, Inc.
药物类别重组蛋白, 细胞治疗
分子靶点F9
给药途径Injectable (Others), Intravenous (IV)
状态Approved

作用机制

分子靶点

nonacog gamma 作用于 1 个分子靶点:

F9coagulation factor IX (P19, F9 p22)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

nonacog gamma 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Congenital, familial and genetic disordersFactor IX deficiency✓ Approved

相关研究文献

PubMedThe Review of scientific instruments2026-11-17

Gamma-electron conversion on MERGS (magnetic electron recoil gamma-ray spectrometers) for fusion diagnostics.

Huber S S, Mackie S S, Kunimune J H JH, Panontin E E et al.

The spectral fingerprint of the radiation emitted by nuclear reactions in fusion experiments contains a wealth of information useful for improving the research and safety of fusion reactor design. In D/T fusion, the branching ratio of neutron emission greatly exceeds that of photon emission by around 5 orders of magnitude [Phys. Rev. Lett. 133, 055102 (2024)], drowning out the gamma ray signal for simpler detector systems, such as scintillators. Investigating novel gamma-ray spectrometers that can filter out these neutrons could prove useful. In this article, we investigate MERGS (Magnetic Electron Recoil Gamma-ray Spectrometer). A collimated neutron/gamma beam impinges upon a thin material in which the high energy photons scatter electrons, which are collimated again by an aperture further down the beamline, then redirected by magnetic optics onto an array of detectors, using the detection location to infer the energy of incident photons. Photon-electron conversion is simulated using a Monte-Carlo method that is explored in this article. Informed by potential future applications, we can place constraints on the design of the conversion material and apertures and can estimate their combined performance. We find that thicker foils offer higher efficiency at the cost of resolution, due to variable slowing dependent on electron scattering location. We find that higher Z conversion materials produce a broader recoil electron spectrum, reducing resolution, due to higher relative rate of pair-production. With these factors in mind, boron is the best non-hazardous element to achieve low noise and broadening. MERGS will enable measurements of gamma spectra from fusion reactors, facilitating safe development of the technology.

PMID 43043115
阅读全文 →
PubMedEJNMMI physics2026-11-17

Pretherapeutic quantitative I-131 SPECT/CT for blood and tumour dosimetry in thyroid cancer patients with bone metastases: a pilot feasibility study.

Kwon Kyounghyoun K, Oh Dongkyu D, Kim Ji Hye JH, Yoo Jihyung J et al.

I-131 radioactive iodine (RAI) is widely used in thyroid cancer patients with bone metastases (BM). While blood-based dosimetry has been standard for predicting marrow toxicity, tumour dosimetry remains an unmet need. We evaluated the feasibility of pretherapeutic quantitative I-131 SPECT/CT for patient-tailored dosimetry in poorly differentiated thyroid carcinoma (PDTC) patients with BM. Five PDTC patients (18 BM lesions) underwent serial pre-therapeutic I-131 SPECT/CT (111 MBq, eight time points up to 120 h) with concurrent blood sampling. I-131 concentrations (MBq/g) were quantified using quantitative SPECT/CT technology and validated against gamma counting. Absorbed dose rates (Gy/h) for blood and tumours were estimated using Monte Carlo simulations (customized Geant4, cross-validated by TOPAS). Tumour absorbed doses were calculated via trapezoidal integration, and clinical outcomes were assessed after subsequent high-dose RAI therapy. Blood I-131 concentrations measured by SPECT/CT showed excellent agreement with gamma counting (p < 0.001). Blood absorbed doses per administered activity were comparable between SPECT/CT and conventional methods (p = 0.6250). Tumour I-131 concentration strongly correlated with absorbed dose rate, resulting in a regression equation [tumour absorbed dose rate (Gy/h) = 0.1256 × tumour RAI concentration (MBq/g) (R2 = 0.9918, p < 0.0001)]. Reducing imaging time points from 8 to 4 maintained the accuracy of absorbed dose estimation. Although exploratory, tumours with expected absorbed doses > 50 Gy after high-dose RAI showed no progression, whereas lower-dose lesions progressed more frequently (87.5%, p = 0.0161). In this pilot study, quantitative I-131 SPECT/CT demonstrated the reliability of pretherapeutic blood and tumour dosimetry in PDTC patients with BM. Although preliminary, these findings support its potential as a practical tool for personalized RAI therapy planning in thyroid cancer. Larger, prospective studies are warranted to validate clinical dose-response thresholds.

PMID 43040069
阅读全文 →
PubMedOptics express2026-11-17

Enhanced radiation resistance and pre-irradiation effects of hydroxyl-containing fluorine-doped silica optical fibers at 1550 nm.

Kim Youngwoong Y, Kim Jongyeol J, Ryu Gukbeen G, Jeong Wookjin W et al.

This study evaluated hydroxyl (OH)-containing, fluorine (F)-doped silica optical fibers developed to enhance radiation resistance for use in high-radiation environments. Fibers with different F and OH concentrations were fabricated using the vapor-phase axial deposition (VAD) process and compared with commercial radiation-hardened fibers under gamma-ray irradiation. The fabricated fibers exhibited superior radiation resistance, with an RIA of 3.7-6.5 dB/km at 100 kGy and 1550 nm, and a pronounced pre-irradiation effect that reduced the RIA at the same dose by up to 78% compared with the first irradiation cycle. These results suggest that the combined F and OH composition is an important factor influencing the radiation resistance and long-term performance of silica optical fibers intended for high-radiation environments.

PMID 43040647
阅读全文 →
PubMedJournal of visualized experiments : JoVE2026-11-17

Generalized Cutaneous Rosai-Dorfman Disease: A Case Report.

Zheng Ji J, Jiao Liang L, Lu Qinglian Q, Wu Wei W

Cutaneous Rosai-Dorfman disease is a rare extranodal presentation of Rosai-Dorfman disease and may clinically mimic inflammatory dermatoses, lymphoma, or other histiocytic disorders. A 62-year-old man presented with a 9-month history of progressively disseminated purplish-red macules and papules involving approximately 70% of the body surface area. No superficial lymphadenopathy was detected, although systemic evaluation was limited. Laboratory findings included mild monocytosis, a positive interferon-gamma release assay, and increased serum free kappa and lambda light chains with a normal ratio. Histopathological examination showed a mixed dermal infiltrate with abundant histiocytic cytoplasm and reported emperipolesis. Immunohistochemistry demonstrated positivity for S100, CD68, CD163, and Cyclin D1, with negativity for CD1a and Langerin, supporting cutaneous Rosai-Dorfman disease. Methylprednisolone and thalidomide were given for approximately 2 weeks, after which the patient stopped treatment because improvement did not meet his expectations and he was concerned about long-term corticosteroid adverse effects. No adverse reaction was reported at discontinuation. At telephone follow-up 1 year after presentation, he reported approximately 90% regression of the lesions; follow-up photographs were unavailable. This case illustrates a generalized cutaneous presentation and subsequent regression after short-course therapy. Treatment-independent spontaneous remission and the complete absence of extracutaneous disease could not be established.

PMID 43042845
阅读全文 →
PubMedOptics express2026-11-17

Analytical Markov chain for spatiotemporal flux evolution of the inner filter effect in fluorescent media.

Yang Xuhui X, Cao Guofu G

Characterizing emission and decay time spectra in multi-component fluorescent media is essential for identifying intrinsic material properties and optimizing detectors. However, wavelength evolution from the secondary inner filter effect (IFE) distorts these observable spectra. While Monte Carlo (MC) ray-tracing can simulate this distortion, accumulating adequate tracking statistics requires long computation times, which hinders parameter optimization within high-dimensional spaces. This paper presents an analytical Markovian transport model based on spatiotemporal decoupling. A Laplace transform converts the multi-nested convolution integrals over continuous domains into a discrete Markov transition matrix, reducing the computational complexity from an exponential scale with respect to wavelength bins N λ and cascade order n, O(N λ n ), to a linear scale, O(N λ +n). The resulting algebraic solutions evaluate transient decay time spectra as a continuum superposition of Gamma wave packets and predict steady-state wavelength spectrum distortions driven by the IFE within a sub-second timescale. Validations across orthogonal and front-face spectrometer configurations show that the calculated spectra match MC simulations in lineshape. This model can serve as a fast forward engine to accelerate parameter space screening, provide early-stage detector design references, and act as a physics-constrained input for event vertex reconstruction algorithms.

PMID 43040698
阅读全文 →
PubMedBritish journal of haematology2026-11-17

Complex karyotype and non-BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia.

Mashima Kiyomi K, Fernandes Stacey M SM, Mikhaleva Mariia M, Azevedo Roberta Santos RS et al.

We retrospectively analysed 646 chronic lymphocytic leukaemia (CLL) patients treated with Bruton tyrosine kinase inhibitors (BTKis) at Dana-Farber Cancer Institute from 2014 to 2023. Among them, 122 underwent next-generation sequencing (NGS) during or at the next office visit after BTKi therapy (ibrutinib [IBR], 85; acalabrutinib [ACA], 23; pirtobrutinib [PIR], 9; vecabrutinib [VEC], 1; zanubrutinib [ZANU], 4). Compared with the non-progressor (NP) group (N = 75), patients with NGS at progression (PD group, N = 47) more commonly had 17p deletion, complex karyotype, heavier prior treatment exposure and prior exposure to a different BTKi before the current regimen. We found 321 mutations in 67 genes, with more mutations in the PD group (231 mutations), including 39 BTK (BTK C481S/F/R/Y, L528W and T474I/L) and 26 phospholipase C gamma 2 (PLCG2) mutations. Among the 12 PD patients with serial samples, all acquired new or expanded BTK or TP53 mutations. Complex karyotype, specifically 8p loss, was significantly enriched in the PD group. tumour protein p53 (TP53), splicing factor 3b subunit 1 (SF3B1), protein phosphatase, Mg2 +/Mn2 + dependent 1D (PPM1D) and notch receptor 2 (NOTCH2) mutations were also significantly more prevalent in the PD group (all p < 0.05). Additionally, pathogenic mitogen-activated protein kinase (MAPK) pathway mutations trended more common and had higher variant allele frequencies (VAFs) in the PD group (p = 0.047). These findings suggest that TP53 aberration and 8p-loss-associated complex karyotype, as well as several non-BTK driver mutations, are enriched in BTKi-resistant patients.

PMID 43041018
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多nonacog gamma